---
title: "Moderna's focus on cancer boosts stock by 177%, pivoting away from Covid-19 vaccine demand drop."
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/296465055.md"
description: "The company experienced a significant decline in its financial performance as demand for Covid-19 vaccines sharply dropped. Despite this setback, the company remained focused on developing another product or service."
datetime: "2026-08-20T09:08:18.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/296465055.md)
  - [en](https://longbridge.com/en/news/296465055.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/296465055.md)
generator: "portal-rs"
---

# Moderna's focus on cancer boosts stock by 177%, pivoting away from Covid-19 vaccine demand drop.

The company experienced a significant decline in its financial performance as demand for Covid-19 vaccines sharply dropped. Despite this setback, the company remained focused on developing another product or service.

### Related Stocks

- [MRNA.US](https://longbridge.com/en/quote/MRNA.US.md)
- [MRNX.US](https://longbridge.com/en/quote/MRNX.US.md)
- [MRNY.US](https://longbridge.com/en/quote/MRNY.US.md)

## Related News & Research

- [Wolfe Research Just Upgraded Moderna Stock. Here's Why.](https://longbridge.com/en/news/296951590.md)
- [Moderna Raises $3.0 Billion via 2032 Zero-Coupon Converts; Adds Capped Calls to Limit Dilution](https://longbridge.com/en/news/297697426.md)
- [Moderna Stock (MRNA) Slides 3% on Plans for a $2B Private Placement](https://longbridge.com/en/news/297195128.md)
- [Moderna plans private placement of $2 billion convertible senior notes offering](https://longbridge.com/en/news/297176043.md)
- [Moderna Announces Pricing of Upsized $2.6 Billion Offering of Convertible Senior Notes  | MRNA Stock News](https://longbridge.com/en/news/297314560.md)

---
> **Disclaimer: This article is for reference only and does not constitute any investment advice.**